MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results
03 mai 2022 16h01 HE
|
MacroGenics, Inc.
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumorsTargeting mid-2022 start of Phase 1...
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call
25 avr. 2022 16h12 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, April 25, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
03 mars 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, March 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Announces Executive Promotion
28 févr. 2022 07h00 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 28, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
MacroGenics Provides Update on Corporate Progress and 2021 Financial Results
24 févr. 2022 16h01 HE
|
MacroGenics, Inc.
Initiating Phase 1 dose escalation study of MGC018 in combination with lorigerlimab (formerly MGD019) in coming weeksPrioritizing MGD024 as lead CD3-based DART® molecule targeting CD123 and...
MacroGenics Announces Date of Fourth Quarter 2021 Financial Results Conference Call
14 févr. 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
03 févr. 2022 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics to Participate in Upcoming Investor Conferences
03 nov. 2021 16h01 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results
02 nov. 2021 16h01 HE
|
MacroGenics, Inc.
Investigational New Drug (IND) application submitted for MGD024, a next generation DART® molecule targeting CD123 and CD3 for AMLU.S. Food & Drug Administration (FDA) approves MacroGenics’ GMP...
MacroGenics Announces Date of Third Quarter 2021 Financial Results Conference Call
26 oct. 2021 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 26, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...